




# *Resilience*



# Corporate Information

## BOARD OF DIRECTORS

### Mr. S. R. Vaidya

*Chairman and Independent Director  
(Appointed Chairman w.e.f. June 16, 2020)*

### Mr. S. N. Kamath

*Managing Director  
(Resigned w.e.f. May 11, 2021)*

### Mr. Gagan Harsh Sharma

*Managing Director  
(Appointed w.e.f. May 11, 2021)*

### Mr. Santosh L. Parab

*Independent Director*

### Ms. Shilpa Bhatia

*Independent Woman Director*

### Dr. Vibha Gagan Sharma

*Whole-Time Director*

### Mrs. Shruti Vishal Rao

*Whole-Time Director*

## REGISTERED OFFICE

102, Hyde Park, Saki Vihar Road,  
Andheri (East), Mumbai - 400 072.  
Phone No.: +91-22-42160000  
Fax No.: +91-22-28563930  
E-Mail: [info@blissgvs.com](mailto:info@blissgvs.com)  
Website: [www.blissgvs.com](http://www.blissgvs.com)

## BANKERS

The Federal Bank Ltd.  
Export Import Bank of India Ltd.

## STATUTORY AUDITORS

Kalyaniwalla & Mistry LLP

## INTERNAL AUDITORS

BDO India LLP

## SECRETARIAL AUDITORS

AVS & Associates

## REGISTRAR AND SHARE TRANSFER AGENT

Universal Capital Securities Pvt. Ltd.  
C-101, 247 Park, LBS Marg, Vikhroli West,  
Mumbai, Maharashtra, 400083.  
Phone No.: +91-22-28207203-05

## MANUFACTURING UNITS

Plot No.: 10, 11 & 12,  
Village: Aliyali, Palghar Taluka, Dist. Thane,  
Maharashtra - 401 404.

Survey No. 43-44,  
Village: Vevoor, Palghar Taluka, Dist. Thane  
Maharashtra - 401404

## RESEARCH & DEVELOPMENT CENTRE

Unit 6, Hyde Park, Saki Vihar Road,  
Andheri (East), Mumbai - 400 072

# Contents

## OVERVIEW

Resilience	2
About BGPL	3
Key Milestones	4
Geographical Presence	5
Manufacturing Facilities	6
Business Overview	8
Research and Development	10
Consolidated Financial Highlights	11
Board of Directors	12
Managing Director's Message to Shareholders	13

## STATUTORY SECTION

Notice	14
Board's Report	34
Management Discussion and Analysis Report	53
Corporate Governance Report	56
Business Responsibility Report	72
CEO/CFO Certificate	77

## FINANCIAL SECTION

Standalone Independent Auditor's Report	81
Standalone Financial Statements	88
Consolidated Independent Auditor's Report	129
Consolidated Financial Statements	136







# Resilience




The world is going through an unprecedented healthcare challenge. The spread of the novel Coronavirus across the globe has brought the global healthcare fraternity together in this most difficult period for humanity. The humanitarian crisis of Coronavirus has shaken up the very core of our existence and has reminded us of how important the healthcare system is.

Bliss GVS Pharma Ltd. (BGPL), has resolved to fight this pandemic by showcasing *Resilience* even in the most uncertain times. The vision of contributing to healthier communities globally has taken on a new meaning and purpose. In this, we strive towards maintaining our competitive stance and dealing with the industry headwinds, while remaining dedicated to constantly innovate and do all that we can to care, cure and nurture good health, thereby improving the quality of human life for all.

We at BGPL hold ourselves to the highest standards when it comes to safety and wellbeing, and in doing so we take utmost care during the entire process from start to finish. Our key brands are spread across therapeutic segments like antimalarial, antifungal, contraceptive, laxative, anti haemorrhoidal, antispasmodic, antibiotic, antimicrobial, antiinflammatory, antipyretic, analgesic, which have been long established by us successfully. Being the world's leading suppositories and pessaries manufacturer and providing contract manufacturing services to renowned pharmaceutical companies, the company is always looking to breaking into new territories, expanding our product basket and achieving new milestones, thus increasing our 'share of mind' by reinvigorating our longstanding client relationships.

Facing the challenges of the New Era of Healthcare, we will continue to move forward on our path with Resilience by committing towards creating a better tomorrow, one step at a time.





# About BGPL

Bliss GVS Pharma Ltd (BGPL) began its humble journey in 1984 with the sole purpose of making healthcare accessible across the world. The company is one of the fast-growing pharmaceutical companies with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. Its portfolio comprises 250+ products that are consumed across 64+ countries with a leading presence in Sub-Saharan Africa and is walking the extra mile to grow in Latin America, Southeast Asia, Europe, and North America.

Over the last decade, BGPL has acquired definitive know-how in other dosage forms & therapeutic segments, which is exemplified by our ever-expanding product offering across more than sixty countries.


BGPL commands a leadership position in antimalarial, antifungal, dermatological, antiinflammatory branded formulations across Sub-Saharan African markets with brands such as Lonart, P-Alaxin, Funbact, and Lofnac, etc, which are supplied in various dosage forms – tablets, suspensions, suppositories and injections etc. The company is a world leader in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment.

R&D is the backbone of our business and a key determinant of our future growth and profitability. Our efforts to move up the pharmaceutical value chain mandate that we keep investing in R&D. The global pharmaceutical landscape is rapidly changing. Hence, businesses of future will need to develop an ability to constantly move up in the pharmaceutical value chain. We continue to be disciplined in identifying future R&D projects for the generics market while simultaneously investing in developing a global specialty portfolio. Given the shifting dynamics of the global pharmaceutical market, progressive investments in R&D is the way forward for us.


The Covid-19 pandemic has disrupted every aspect of human life around the world. We, at BGPL, are committed to contributing to the global effort to combat this pandemic. The new normal is here to stay and presents a unique opportunity for the Indian pharma industry to enhance its position as the largest provider of generics globally and emerge out of this crisis as a preferred sourcing hub for the world.

Our business in India and the world continues to strengthen, despite challenges that the financial year 2020-21 brought upon the whole world. With the growing demand across geographies, enhanced R&D and production capabilities and also a diversified product portfolio across dosage forms and therapeutic segments the company is well placed to have a sustainable growth in the future.





# Key Milestones



# Geographical Presence


## Operations in 60+ Countries

### AFRICA


Angola  
Benin  
Botswana  
Burkina Faso  
Burundi  
Cameroon  
Central African Republic  
Chad  
Cote d'Ivoire  
Dem. Rep. Congo  
Ethiopia  
Gabon  
Gambia

Ghana  
Guinea  
Kenya  
Lesotho  
Liberia  
Libya  
Malawi  
Mali  
Mauritania  
Mauritius  
Mozambique  
Namibia  
Niger  
Nigeria





With its strong foothold presence in more than 64 countries, and a leading presence in Sub-Saharan Africa, BGPL is walking the extra mile to conquer Latin America, Southeast Asia, Europe, and North America. The company has successfully gained expertise in serving these diverse geographies for more than 30 years and delivering life-saving products that add value to the lives of the patients. After gaining a leading presence in Africa, the company is now strengthening its presence in other markets. BGPL has received the Russian GMP approval for the suppository manufacturing facility located in Palghar.



Rep. of Congo  
Rwanda  
Senegal  
Sierra Leone  
South Sudan  
Sudan  
Tanzania  
Togo  
Uganda  
Zambia  
Zimbabwe

#### ASIA

Afghanistan  
Bhutan  
India  
Macau  
Nepal

#### CIS

Kazakhstan  
Kyrgyzstan  
Tajikistan  
Turkmenistan  
Uzbekistan  
Russia (PE)

#### EUROPE

France  
Romania  
United Kingdom  
Latvia (PE)  
Netherlands (PE)  
Portugal (PE)

#### MIDDLE EAST

Iraq  
Jordan  
Lebanon  
Qatar  
UAE  
Yemen

#### CENTRAL AMERICA

Costa Rica  
Guatemala  
Honduras  
Panama

#### NORTH AMERICA

Canada  
USA

#### OCEANIA

Fiji  
New Zealand  
Pap. New Guinea  
Australia (PE)

#### SOUTH EAST ASIA


Bangladesh  
Cambodia  
Hong Kong  
Laos  
Malaysia  
Maldives  
Sri Lanka  
Myanmar (OO)  
Philippines (OO)  
Singapore (RO)  
Vietnam (RO)

PE - Planned Expansion

RO - Existing - Rep. Office



OO - Own Offices








# Manufacturing Facilities

BGPL has 5 state-of-the-art manufacturing facilities which are WHO-GMP, EU-GMP, ISO 14001 and OHSAS 45001 compliant.







## Vevoor Plant

### Multi-Dose Manufacturing Facility

The state-of-the-art manufacturing facility at Vevoor, Maharashtra, with a total area of 19,000 Sq. Mt., was primarily kick started to expand our capacities, in order to meet the growing client demand. The plant was conceptualised in two phases. The first phase was commissioned earlier in March, 2020, primarily for Tablets, Capsules, Dry Syrups, and Sachets. While the second phase commenced construction in January, 2021, primarily for Sachets, Suppositories, Ointments, Tablets and Capsules. In spite of the current ongoing pandemic, the civil work for the plant is expected to get completed during the current financial year.



Further, to maintain high quality standards the plant is approved by the Indian Central Drugs Standard Control Organization (CDSCO) and Kenya GMP to supply the best quality products to the patients. Moreover, solar power panels have been deployed within the premises of the plant, which will accommodate 30% of energy requirements resulting in cost savings.


The company has further undertaken to scale up the renewable energy based electricity generation to about 4 megawatt in the current financial year, which is designed to be further expanded to 6 MW in line with our energy consumption requirements based on the capacity addition. This initiative shall lead to a significant reduction in our carbon footprint and meet about of 80% of the company's power consumption need for manufacturing activities. This initiative is also expected to yield in significant saving in our energy costs.



# Business Overview

## Therapeutic Segments

BGPL's Product portfolio comprises 250+ branded formulations across 20+ therapeutic segments



## Leader in Anti-malarial

BGPL has established itself as a prominent competitor in the anti-malarial branded formulations area, which has potential considering that malaria cases on the African continent account for 90% of all malaria cases worldwide. Lonart and P-Alaxin, two anti-malarial medicines owned by BGPL, are market leaders in their respective areas in East and West Africa.



## List of Therapeutic Segments

**Antimalarial** | **Antifungal** | **Antibacterial** | **Antiinflammatory** | **Antibiotic**

## Key Brands in Cream and Ointment Segment

Funbact - A



Lofnac gel

